Raymond James lowered the firm’s price target on Boston Scientific (BSX) to $121 from $122 and keeps a Strong Buy rating on the shares. Boston Scientific exceeded a high bar with Q1 results and the raised 2025 guidance, the analyst tells investors in a research note. While growth will naturally decelerate going forward, given the comps, with Q1 results, Boston Scientific has reinforced its status as a top-tier grower in Med Tech, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $115 at Baird
- Boston Scientific’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Strong Q1 2025 Performance and Growth Potential Justifies Buy Rating
- Boston Scientific: Strong Financial Performance and Positive Outlook Support Buy Rating
- Boston Scientific’s Strong Growth and Strategic Resilience Earns Buy Rating